» Articles » PMID: 27376268

PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2016 Jul 5
PMID 27376268
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

PD-1/PD-L1 (programmed death 1/programmed death ligand 1) pathway plays a critical role in immune escape of tumor cells. Recent studies have described that PD-L1 is heterogeneously expressed in various types of cancer, although its prognostic/predictive value is still uncertain. These problems are partly due to a not well defined operating protocol for its detection by immunohistochemistry, but also because most of the studies conducted on large case series were made by Tissue Micro Array (TMA). We are going to discuss this latter point, to highlight that TMA must be set up in an appropriate manner, especially for some markers, such as PD-L1, which, besides being poorly expressed in tumor cells, can be expressed by cells of the tumor microenvironment.

Citing Articles

Tissue microarray validation in cervical carcinoma studies. A methodological approach.

Lovane L, Carrilho C, Karlsson C Histol Histopathol. 2024; 40(3):317-325.

PMID: 39086316 DOI: 10.14670/HH-18-796.


Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study.

Pena-Cardelles J, Pozo-Kreilinger J, Roncador G, Esteban-Hernandez J, Moro-Rodriguez J, Sastre-Perona A Biomedicines. 2022; 10(3).

PMID: 35327512 PMC: 8945047. DOI: 10.3390/biomedicines10030710.


PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer.

Wei X, Luo X, Sheng H, Wang Y, Chen D, Li J J Transl Med. 2020; 18(1):475.

PMID: 33308232 PMC: 7730753. DOI: 10.1186/s12967-020-02636-x.


Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion.

Minopoli M, Botti G, Gigantino V, Ragone C, Sarno S, Motti M J Exp Clin Cancer Res. 2019; 38(1):459.

PMID: 31703596 PMC: 6839174. DOI: 10.1186/s13046-019-1465-8.


The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma.

Lee A, Chew W, Wilding C, Guljar N, Smith M, Strauss D Sci Rep. 2019; 9(1):14602.

PMID: 31601875 PMC: 6787212. DOI: 10.1038/s41598-019-50888-5.


References
1.
Scognamiglio G, De Chiara A, di Bonito M, Tatangelo F, Losito N, Anniciello A . Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. Int J Mol Sci. 2016; 17(5). PMC: 4881606. DOI: 10.3390/ijms17050790. View

2.
McLaughlin J, Han G, Schalper K, Carvajal-Hausdorf D, Pelekanou V, Rehman J . Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol. 2015; 2(1):46-54. PMC: 4941982. DOI: 10.1001/jamaoncol.2015.3638. View

3.
Muenst S, Schaerli A, Gao F, Daster S, Trella E, Droeser R . Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014; 146(1):15-24. PMC: 4180714. DOI: 10.1007/s10549-014-2988-5. View

4.
Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

5.
Wu P, Wu D, Li L, Chai Y, Huang J . PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One. 2015; 10(6):e0131403. PMC: 4483169. DOI: 10.1371/journal.pone.0131403. View